RxDoctor Payments Data

Kayla Reid

Nurse Practitioner · Roanoke, VANPI 1669157707

Payments from drug & device makers

$3,532in general payments, 2019–2025

Across 199 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$664
  • AstraZeneca$416
  • Pfizer$358
  • AbbVie$348
  • Lilly USA, LLC$340
  • Amgen$304
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,532 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$98,984
Medicare patients
193
Services billed
2,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$50,659
OzempicSemaglutide42$49,273
RybelsusSemaglutide50$47,973
FarxigaDapagliflozin Propanediol53$44,286
VraylarCariprazine Hcl20$30,444
MounjaroTirzepatide20$21,678
XareltoRivaroxaban11$17,249
JardianceEmpagliflozin11$8,266
SymbicortBudesonide/Formoterol Fumarate17$4,933
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$2,740
Celecoxib43$1,854
Levothyroxine Sodium176$1,754
Rosuvastatin Calcium204$1,721
Duloxetine Hcl51$1,705
Atorvastatin Calcium167$1,535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$664$97,24592 claims
PfizerEliquis$358$50,65956 claims
AstraZenecaFarxiga, Symbicort$416$49,21970 claims
AbbVieVraylar$348$30,44420 claims
Lilly USA, LLCMounjaro$340$21,67820 claims
Johnson & JohnsonXarelto$120$17,24911 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$1,754176 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →